{"id":1645,"date":"2026-08-21T11:22:07","date_gmt":"2026-08-21T09:22:07","guid":{"rendered":"https:\/\/infoimasd.com\/?p=1645"},"modified":"2026-08-21T11:22:08","modified_gmt":"2026-08-21T09:22:08","slug":"vacuna-moderna-melanoma-reduce-recaida","status":"publish","type":"post","link":"https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/","title":{"rendered":"La vacuna personalizada de Moderna reduce el riesgo de reca\u00edda del melanoma en un ensayo de fase 3"},"content":{"rendered":"\n<p class=\"has-medium-font-size wp-block-paragraph\">Una <strong>vacuna personalizada basada en ARN mensajero desarrollada por Moderna y Merck<\/strong> ha obtenido resultados positivos en un ensayo cl\u00ednico de fase 3 para pacientes con melanoma de alto riesgo. El tratamiento, dise\u00f1ado espec\u00edficamente a partir de las caracter\u00edsticas gen\u00e9ticas de cada tumor, ha demostrado <strong>reducir de forma significativa el riesgo de que el c\u00e1ncer vuelva a aparecer o se extienda despu\u00e9s de la cirug\u00eda.<\/strong><\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">El candidato, denominado intismeran autogene (mRNA-4157\/V940), se administra en combinaci\u00f3n con pembrolizumab, el principio activo de Keytruda, una inmunoterapia ya utilizada contra distintos tipos de c\u00e1ncer. El ensayo INTerpath-001 incluy\u00f3 a 1.137 pacientes con melanoma de alto riesgo cuyos tumores hab\u00edan sido extirpados quir\u00fargicamente. Los resultados anunciados por las compa\u00f1\u00edas muestran <strong>mejoras estad\u00edsticamente significativas tanto en la supervivencia libre de reca\u00edda como en la supervivencia libre de met\u00e1stasis a distancia.<\/strong><\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">A diferencia de las vacunas tradicionales, que preparan al organismo frente a un microorganismo antes de que se produzca una infecci\u00f3n, <strong>esta tecnolog\u00eda utiliza el ARN mensajero para ense\u00f1ar al sistema inmunitario a reconocer caracter\u00edsticas espec\u00edficas de las c\u00e9lulas tumorales.<\/strong> Para ello, los investigadores analizan el tumor extirpado e identifican mutaciones que pueden generar neoant\u00edgenos, mol\u00e9culas caracter\u00edsticas de las c\u00e9lulas cancerosas.<\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">Con esa informaci\u00f3n se fabrica una vacuna individualizada que puede incluir hasta 34 neoant\u00edgenos espec\u00edficos del tumor de cada paciente. <strong>El objetivo es que el sistema inmunitario aprenda a identificar esas se\u00f1ales y destruya las c\u00e9lulas cancerosas que puedan haber quedado en el organismo despu\u00e9s de la cirug\u00eda. <\/strong>La estrategia se combina con pembrolizumab, que ayuda a mantener activada la respuesta inmunitaria contra el tumor. El tratamiento no pretende sustituir a la cirug\u00eda para eliminar un melanoma existente, sino <strong>reducir la posibilidad de que reaparezca posteriormente. <\/strong>Este matiz es importante porque no se trata de una vacuna preventiva contra el c\u00e1ncer que pueda administrarse a personas sanas.<\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-rich is-provider-x wp-block-embed-x\"><div class=\"wp-block-embed__wrapper\">\n<blockquote class=\"twitter-tweet\" data-width=\"500\" data-dnt=\"true\"><p lang=\"en\" dir=\"ltr\">Moderna and <a href=\"https:\/\/x.com\/Merck?ref_src=twsrc%5Etfw\">@Merck<\/a> today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination\u2026 <a href=\"https:\/\/t.co\/v4DjH0r823\">pic.twitter.com\/v4DjH0r823<\/a><\/p>&mdash; Moderna (@moderna_tx) <a href=\"https:\/\/x.com\/moderna_tx\/status\/2090029002735882492?ref_src=twsrc%5Etfw\">August 19, 2026<\/a><\/blockquote><script async src=\"https:\/\/platform.x.com\/widgets.js\" charset=\"utf-8\"><\/script>\n<\/div><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">El ensayo de fase 3 alcanza sus objetivos<\/h3>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">Los resultados anunciados ahora corresponden al ensayo internacional INTerpath-001, en el que participaron 35 hospitales de 26 pa\u00edses. Los pacientes fueron distribuidos entre un grupo que recibi\u00f3 pembrolizumab y otro que recibi\u00f3 la combinaci\u00f3n de pembrolizumab e intismeran autogene.<\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">Las compa\u00f1\u00edas han comunicado que la combinaci\u00f3n alcanz\u00f3 los dos objetivos principales del estudio: <strong>mejorar la supervivencia libre de reca\u00edda y la supervivencia libre de met\u00e1stasis a distancia. <\/strong>Los datos detallados todav\u00eda no han sido publicados en una revista cient\u00edfica ni presentados en profundidad en un congreso m\u00e9dico, por lo que habr\u00e1 que esperar para conocer las cifras completas y valorar con mayor precisi\u00f3n la magnitud del beneficio.<\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">El resultado supone un paso especialmente relevante porque <strong>se trata de uno de los primeros desarrollos de una vacuna personalizada contra el c\u00e1ncer basada en ARN mensajero que alcanza resultados positivos en un ensayo de fase 3. <\/strong>Moderna y MSD prev\u00e9n presentar los resultados completos y avanzar en los procesos de evaluaci\u00f3n regulatoria.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Una estrategia que ya hab\u00eda mostrado resultados<\/h3>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">El anuncio de fase 3 llega despu\u00e9s de los resultados obtenidos en el ensayo de fase 2b KEYNOTE-942, que ya hab\u00edan mostrado una reducci\u00f3n considerable del riesgo de reca\u00edda. En la actualizaci\u00f3n publicada en 2024, <strong>la combinaci\u00f3n de mRNA-4157 y pembrolizumab redujo un 49% el riesgo de reca\u00edda o muerte y un 62% el riesgo de met\u00e1stasis a distancia o muerte frente a pembrolizumab en solitario.<\/strong><\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\"><strong>El seguimiento a cinco a\u00f1os tambi\u00e9n ha mantenido la reducci\u00f3n del 49% en el riesgo de reca\u00edda o muerte observada en ese estudio<\/strong>, reforzando la hip\u00f3tesis de que la respuesta inmunitaria generada por la vacuna puede mantenerse en el tiempo. El ensayo de fase 2b, sin embargo, fue mucho m\u00e1s peque\u00f1o, con 157 pacientes, por lo que los resultados del estudio de fase 3 son especialmente importantes para confirmar la eficacia en una poblaci\u00f3n mucho m\u00e1s amplia.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Seis hospitales espa\u00f1oles participaron en el desarrollo<\/h3>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">Espa\u00f1a tambi\u00e9n ha tenido un papel en esta investigaci\u00f3n. <strong>Seis hospitales espa\u00f1oles participaron en el ensayo internacional de fase 3<\/strong>, <strong>con el Hospital Regional Universitario de M\u00e1laga como uno de los centros que m\u00e1s pacientes incorpor\u00f3. <\/strong>La participaci\u00f3n espa\u00f1ola forma parte de una red internacional de 35 hospitales distribuidos por 26 pa\u00edses. La participaci\u00f3n de los centros espa\u00f1oles resulta especialmente relevante para el posible desarrollo de esta nueva generaci\u00f3n de tratamientos personalizados. Si finalmente recibe autorizaci\u00f3n, su utilizaci\u00f3n requerir\u00e1 coordinar el diagn\u00f3stico molecular del tumor, el dise\u00f1o de la vacuna y su fabricaci\u00f3n individualizada antes de administrarla al paciente.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">El siguiente reto: llevar la vacuna a otros tumores<\/h3>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">El inter\u00e9s de la tecnolog\u00eda va m\u00e1s all\u00e1 del melanoma. <strong>Moderna y Merck est\u00e1n estudiando el mismo enfoque en otros tipos de c\u00e1ncer, entre ellos tumores de pulm\u00f3n, vejiga, ri\u00f1\u00f3n, p\u00e1ncreas y est\u00f3mago.<\/strong> La idea es aplicar la misma l\u00f3gica: identificar las mutaciones caracter\u00edsticas de cada tumor y utilizar una vacuna de ARN mensajero para entrenar al sistema inmunitario contra esas c\u00e9lulas.<\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">Sin embargo, <strong>los buenos resultados en melanoma no garantizan que la estrategia vaya a funcionar de la misma manera en otros tumores<\/strong>. El melanoma presenta caracter\u00edsticas biol\u00f3gicas que lo hacen particularmente susceptible a determinadas inmunoterapias, por lo que ser\u00e1n necesarios nuevos ensayos para comprobar hasta d\u00f3nde puede extenderse esta tecnolog\u00eda.<\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">La vacuna representa, en cualquier caso, un cambio de enfoque significativo en oncolog\u00eda. Si los resultados de fase 3 se confirman con los datos completos y el tratamiento obtiene las correspondientes autorizaciones,<strong> las vacunas personalizadas de ARN mensajero podr\u00edan convertirse en una nueva herramienta para reducir las reca\u00eddas despu\u00e9s de la cirug\u00eda y abrir una v\u00eda de investigaci\u00f3n<\/strong> hacia tratamientos individualizados frente a otros tipos de c\u00e1ncer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La vacuna personalizada de ARN mensajero de Moderna y MSD ha alcanzado los objetivos de un ensayo de fase 3 y podr\u00eda convertirse en una nueva herramienta para evitar la reca\u00edda del melanoma.<\/p>\n","protected":false},"author":1,"featured_media":1647,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[11],"tags":[720,379,194,721,723,724,725,718,499,722],"class_list":["post-1645","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investigacion","tag-arn-mensajero","tag-biotecnologia","tag-cancer","tag-inmunoterapia","tag-investigacion-medica","tag-melanoma","tag-merck","tag-moderna","tag-oncologia","tag-vacunas"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La vacuna personalizada de Moderna reduce el riesgo de reca\u00edda del melanoma en un ensayo de fase 3 - INFO I+D<\/title>\n<meta name=\"description\" content=\"La vacuna personalizada de Moderna y MSD reduce el riesgo de reca\u00edda del melanoma en un ensayo cl\u00ednico de fase 3.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La vacuna personalizada de Moderna reduce el riesgo de reca\u00edda del melanoma en un ensayo de fase 3 - INFO I+D\" \/>\n<meta property=\"og:description\" content=\"La vacuna personalizada de Moderna y MSD reduce el riesgo de reca\u00edda del melanoma en un ensayo cl\u00ednico de fase 3.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/\" \/>\n<meta property=\"og:site_name\" content=\"INFO I+D\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-21T09:22:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-21T09:22:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/08\/Vacuna-scaled-e1787304053792.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Miguel Guti\u00e9rrez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Miguel Guti\u00e9rrez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/08\\\/21\\\/vacuna-moderna-melanoma-reduce-recaida\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/08\\\/21\\\/vacuna-moderna-melanoma-reduce-recaida\\\/\"},\"author\":{\"name\":\"Miguel Guti\u00e9rrez\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#\\\/schema\\\/person\\\/7d19b1faaeac5b8ab56fbdb8f46fc85e\"},\"headline\":\"La vacuna personalizada de Moderna reduce el riesgo de reca\u00edda del melanoma en un ensayo de fase 3\",\"datePublished\":\"2026-08-21T09:22:07+00:00\",\"dateModified\":\"2026-08-21T09:22:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/08\\\/21\\\/vacuna-moderna-melanoma-reduce-recaida\\\/\"},\"wordCount\":1032,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/08\\\/21\\\/vacuna-moderna-melanoma-reduce-recaida\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Vacuna-scaled-e1787304053792.jpg\",\"keywords\":[\"ARN mensajero\",\"Biotecnolog\u00eda\",\"C\u00e1ncer\",\"inmunoterapia\",\"investigaci\u00f3n m\u00e9dica\",\"melanoma\",\"Merck\",\"Moderna\",\"oncolog\u00eda\",\"vacunas\"],\"articleSection\":[\"Investigaci\u00f3n\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/08\\\/21\\\/vacuna-moderna-melanoma-reduce-recaida\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/08\\\/21\\\/vacuna-moderna-melanoma-reduce-recaida\\\/\",\"url\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/08\\\/21\\\/vacuna-moderna-melanoma-reduce-recaida\\\/\",\"name\":\"La vacuna personalizada de Moderna reduce el riesgo de reca\u00edda del melanoma en un ensayo de fase 3 - INFO I+D\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/08\\\/21\\\/vacuna-moderna-melanoma-reduce-recaida\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/08\\\/21\\\/vacuna-moderna-melanoma-reduce-recaida\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Vacuna-scaled-e1787304053792.jpg\",\"datePublished\":\"2026-08-21T09:22:07+00:00\",\"dateModified\":\"2026-08-21T09:22:08+00:00\",\"description\":\"La vacuna personalizada de Moderna y MSD reduce el riesgo de reca\u00edda del melanoma en un ensayo cl\u00ednico de fase 3.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/08\\\/21\\\/vacuna-moderna-melanoma-reduce-recaida\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/08\\\/21\\\/vacuna-moderna-melanoma-reduce-recaida\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/08\\\/21\\\/vacuna-moderna-melanoma-reduce-recaida\\\/#primaryimage\",\"url\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Vacuna-scaled-e1787304053792.jpg\",\"contentUrl\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Vacuna-scaled-e1787304053792.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/08\\\/21\\\/vacuna-moderna-melanoma-reduce-recaida\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/infoimasd.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La vacuna personalizada de Moderna reduce el riesgo de reca\u00edda del melanoma en un ensayo de fase 3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#website\",\"url\":\"https:\\\/\\\/infoimasd.com\\\/\",\"name\":\"infoimasd.com\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/infoimasd.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#organization\",\"name\":\"INFO I+D\",\"url\":\"https:\\\/\\\/infoimasd.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Logo-INFO-ID-RELIEVE-150-X-150.png\",\"contentUrl\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Logo-INFO-ID-RELIEVE-150-X-150.png\",\"width\":1254,\"height\":1254,\"caption\":\"INFO I+D\"},\"image\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#\\\/schema\\\/person\\\/7d19b1faaeac5b8ab56fbdb8f46fc85e\",\"name\":\"Miguel Guti\u00e9rrez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/litespeed\\\/avatar\\\/8bbe81d383fcd5d10975c32a324d8b3d.jpg?ver=1790012860\",\"url\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/litespeed\\\/avatar\\\/8bbe81d383fcd5d10975c32a324d8b3d.jpg?ver=1790012860\",\"contentUrl\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/litespeed\\\/avatar\\\/8bbe81d383fcd5d10975c32a324d8b3d.jpg?ver=1790012860\",\"caption\":\"Miguel Guti\u00e9rrez\"},\"description\":\"Director de INFO I+D\",\"sameAs\":[\"https:\\\/\\\/infoimasd.com\\\/\"],\"url\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/author\\\/admin8536\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La vacuna personalizada de Moderna reduce el riesgo de reca\u00edda del melanoma en un ensayo de fase 3 - INFO I+D","description":"La vacuna personalizada de Moderna y MSD reduce el riesgo de reca\u00edda del melanoma en un ensayo cl\u00ednico de fase 3.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/","og_locale":"es_ES","og_type":"article","og_title":"La vacuna personalizada de Moderna reduce el riesgo de reca\u00edda del melanoma en un ensayo de fase 3 - INFO I+D","og_description":"La vacuna personalizada de Moderna y MSD reduce el riesgo de reca\u00edda del melanoma en un ensayo cl\u00ednico de fase 3.","og_url":"https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/","og_site_name":"INFO I+D","article_published_time":"2026-08-21T09:22:07+00:00","article_modified_time":"2026-08-21T09:22:08+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/08\/Vacuna-scaled-e1787304053792.jpg","type":"image\/jpeg"}],"author":"Miguel Guti\u00e9rrez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Miguel Guti\u00e9rrez","Tiempo de lectura":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/#article","isPartOf":{"@id":"https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/"},"author":{"name":"Miguel Guti\u00e9rrez","@id":"https:\/\/infoimasd.com\/#\/schema\/person\/7d19b1faaeac5b8ab56fbdb8f46fc85e"},"headline":"La vacuna personalizada de Moderna reduce el riesgo de reca\u00edda del melanoma en un ensayo de fase 3","datePublished":"2026-08-21T09:22:07+00:00","dateModified":"2026-08-21T09:22:08+00:00","mainEntityOfPage":{"@id":"https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/"},"wordCount":1032,"commentCount":0,"publisher":{"@id":"https:\/\/infoimasd.com\/#organization"},"image":{"@id":"https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/#primaryimage"},"thumbnailUrl":"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/08\/Vacuna-scaled-e1787304053792.jpg","keywords":["ARN mensajero","Biotecnolog\u00eda","C\u00e1ncer","inmunoterapia","investigaci\u00f3n m\u00e9dica","melanoma","Merck","Moderna","oncolog\u00eda","vacunas"],"articleSection":["Investigaci\u00f3n"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/","url":"https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/","name":"La vacuna personalizada de Moderna reduce el riesgo de reca\u00edda del melanoma en un ensayo de fase 3 - INFO I+D","isPartOf":{"@id":"https:\/\/infoimasd.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/#primaryimage"},"image":{"@id":"https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/#primaryimage"},"thumbnailUrl":"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/08\/Vacuna-scaled-e1787304053792.jpg","datePublished":"2026-08-21T09:22:07+00:00","dateModified":"2026-08-21T09:22:08+00:00","description":"La vacuna personalizada de Moderna y MSD reduce el riesgo de reca\u00edda del melanoma en un ensayo cl\u00ednico de fase 3.","breadcrumb":{"@id":"https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/#primaryimage","url":"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/08\/Vacuna-scaled-e1787304053792.jpg","contentUrl":"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/08\/Vacuna-scaled-e1787304053792.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/infoimasd.com\/index.php\/2026\/08\/21\/vacuna-moderna-melanoma-reduce-recaida\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/infoimasd.com\/"},{"@type":"ListItem","position":2,"name":"La vacuna personalizada de Moderna reduce el riesgo de reca\u00edda del melanoma en un ensayo de fase 3"}]},{"@type":"WebSite","@id":"https:\/\/infoimasd.com\/#website","url":"https:\/\/infoimasd.com\/","name":"infoimasd.com","description":"","publisher":{"@id":"https:\/\/infoimasd.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/infoimasd.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/infoimasd.com\/#organization","name":"INFO I+D","url":"https:\/\/infoimasd.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/infoimasd.com\/#\/schema\/logo\/image\/","url":"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/05\/Logo-INFO-ID-RELIEVE-150-X-150.png","contentUrl":"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/05\/Logo-INFO-ID-RELIEVE-150-X-150.png","width":1254,"height":1254,"caption":"INFO I+D"},"image":{"@id":"https:\/\/infoimasd.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/infoimasd.com\/#\/schema\/person\/7d19b1faaeac5b8ab56fbdb8f46fc85e","name":"Miguel Guti\u00e9rrez","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/infoimasd.com\/wp-content\/litespeed\/avatar\/8bbe81d383fcd5d10975c32a324d8b3d.jpg?ver=1790012860","url":"https:\/\/infoimasd.com\/wp-content\/litespeed\/avatar\/8bbe81d383fcd5d10975c32a324d8b3d.jpg?ver=1790012860","contentUrl":"https:\/\/infoimasd.com\/wp-content\/litespeed\/avatar\/8bbe81d383fcd5d10975c32a324d8b3d.jpg?ver=1790012860","caption":"Miguel Guti\u00e9rrez"},"description":"Director de INFO I+D","sameAs":["https:\/\/infoimasd.com\/"],"url":"https:\/\/infoimasd.com\/index.php\/author\/admin8536\/"}]}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/08\/Vacuna-scaled-e1787304053792.jpg","_links":{"self":[{"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/posts\/1645","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/comments?post=1645"}],"version-history":[{"count":1,"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/posts\/1645\/revisions"}],"predecessor-version":[{"id":1646,"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/posts\/1645\/revisions\/1646"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/media\/1647"}],"wp:attachment":[{"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/media?parent=1645"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/categories?post=1645"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/tags?post=1645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}